Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1Abatacept, rituximab or tocilizumab
(Rituxan (TN))		3件: Abatacept,
Rituximab (Rituxan Sc),
Tocilizumab		3件: Tocilizumab ,
Rituximab (Rituxan (TN)),
Abatacept 💬 		4件: CD80,
CD86,
IL6R,
MS4A1 💬 		25件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus 💬1件: 46 💬
2ABP 798 - Biosimilar to rituximab
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
3ABP 798 Biosimilar to Rituximab
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
4Administration of rituximab and methylprednisolone
(Rituxan (TN))		2件: Methylprednisolone,
Rituximab (Rituxan Sc)		2件: Methylprednisolone ,
Rituximab (Rituxan (TN)) 💬 		2件: MS4A1,
NR3C1 💬 		2件: Hematopoietic cell lineage, Neuroactive ligand-receptor interaction 💬1件: 51 💬
5Alemtuzumab and Rituximab
(Rituxan (TN))		2件: Alemtuzumab,
Rituximab (Rituxan Sc)		2件: Alemtuzumab ,
Rituximab (Rituxan (TN)) 💬 		2件: CD52,
MS4A1 💬 		1件: Hematopoietic cell lineage 💬1件: 60 💬
6Alemtuzumab, Rituximab
(Rituxan (TN))		2件: Alemtuzumab,
Rituximab (Rituxan Sc)		2件: Alemtuzumab ,
Rituximab (Rituxan (TN)) 💬 		2件: CD52,
MS4A1 💬 		1件: Hematopoietic cell lineage 💬1件: 63 💬
7Arm B: Rituxan®/Mabthera®1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
8Belimumab in SLE patients / Rituximab in RA patients
(Rituxan (TN))		2件: Belimumab,
Rituximab (Rituxan Sc)		2件: Rituximab (Rituxan (TN)),
Belimumab 💬 		2件: MS4A1,
TNFSF13B 💬 		5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬2件: 46, 49 💬
9Bendamustine, Rituximab
(Rituxan (TN))		2件: Bendamustine,
Rituximab (Rituxan Sc)		2件: Rituximab (Rituxan (TN)),
Bendamustine 💬 		1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 61 💬
10Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine
(Rituxan (TN))		3件: Azathioprine,
Dexamethasone,
Rituximab (Rituxan Sc)		3件: Azathioprine ,
Dexamethasone ,
Rituximab (Rituxan (TN)) 💬 		2件: MS4A1,
NR3C1 💬 		2件: Hematopoietic cell lineage, Neuroactive ligand-receptor interaction 💬1件: 35 💬
11Combination of Rituximab
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 63 💬
12Combination of Rituximab with subcutaneous belimumab
(Rituxan (TN))		2件: Belimumab,
Rituximab (Rituxan Sc)		2件: Rituximab (Rituxan (TN)),
Belimumab 💬 		2件: MS4A1,
TNFSF13B 💬 		5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 63 💬
13Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 85 💬
14Cyclophosphamide/Rituximab
(Rituxan (TN))		2件: Cyclophosphamide,
Rituximab (Rituxan Sc)		3件: Cyclophosphamide ,
Rituximab (Rituxan (TN)),
Cyclophosphamide 💬 		1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 13 💬
15Dexamethasone and Rituximab
(Rituxan (TN))		2件: Dexamethasone,
Rituximab (Rituxan Sc)		2件: Dexamethasone ,
Rituximab (Rituxan (TN)) 💬 		2件: MS4A1,
NR3C1 💬 		2件: Hematopoietic cell lineage, Neuroactive ligand-receptor interaction 💬1件: 63 💬
16Double-Blind Rituximab
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 51 💬
17Dr. Reddy’s Rituximab (DRL_RI) 100mg
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
18Dr. Reddy’s Rituximab (DRL_RI) 500mg
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
19Eltrombopag combining rituximab
(Rituxan (TN))		2件: Eltrombopag,
Rituximab (Rituxan Sc)		1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 63 💬
20Etanercepet, Rituximab, Abatacept, Tocilizumab, Sarilumab
(Rituxan (TN))		4件: Abatacept,
Rituximab (Rituxan Sc),
Sarilumab,
Tocilizumab		4件: Tocilizumab ,
Rituximab (Rituxan (TN)),
Abatacept ,
Sarilumab 💬 		4件: CD80,
CD86,
IL6R,
MS4A1 💬 		25件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus 💬1件: 46 💬
21Experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 222 💬
22GP2013 - A Proposed biosimilar rituximab
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
23IDEC-C2B8 (rituximab)
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
24Immunosuppressive treatment (eg, rituximab)
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 64 💬
25Individualized dose of rituximab
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 49 💬
26Interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
(Rituxan (TN))		12件: Acetate,
Alemtuzumab,
Cladribine,
Dimethyl fumarate,
Fingolimod,
Glatiramer,
Natalizumab,
Ocrelizumab,
Ofatumumab,
Ponesimod,
Rituximab (Rituxan Sc),
Teriflunomide		10件: Cladribine ,
Alemtuzumab ,
Rituximab (Rituxan (TN)),
Dimethyl fumarate ,
Ocrelizumab ,
Natalizumab ,
Ofatumumab ,
Fingolimod ,
Teriflunomide ,
Ponesimod 💬 		7件: CD52,
DHODH,
ITGA4,
KEAP1,
MS4A1,
RRM1,
S1PR1 💬 		30件: Arrhythmogenic right ventricular cardiomyopathy, Biosynthesis of cofactors, Cell adhesion molecules, Chemical carcinogenesis - reactive oxygen species, Dilated cardiomyopathy, Drug metabolism - other enzymes, ECM-receptor interaction, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Glutathione metabolism, Hematopoietic cell lineage, Hepatocellular carcinoma, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, Metabolic pathways, Neuroactive ligand-receptor interaction, Nucleotide metabolism, PI3K-Akt signaling pathway, Parkinson disease, Pathways in cancer, Purine metabolism, Pyrimidine metabolism, Regulation of actin cytoskeleton, Sphingolipid signaling pathway, Ubiquitin mediated proteolysis, Yersinia infection 💬1件: 13 💬
27Intravenous Rituximab
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 66 💬
28MabionCD20 (candidate biosimilar to rituximab)
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
29MabThera (Rituximab)
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬4件: 13, 46, 49, 53 💬
30Mabthera or biosimilar Rituximab
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 61 💬
31Mabthera or biosimilar rituximab product
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 13 💬
32MabThera/Rituxan1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
33MabThera® (rituximab)
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
34Originator rituximab - Rituxan ® or MabThera ®1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
35Perfusion of treatment Rituximab
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 13 💬
36Prednisone, low dose rituximab
(Rituxan (TN))		2件: Prednisone,
Rituximab (Rituxan Sc)		2件: Prednisone ,
Rituximab (Rituxan (TN)) 💬 		2件: MS4A1,
NR3C1 💬 		2件: Hematopoietic cell lineage, Neuroactive ligand-receptor interaction 💬1件: 61 💬
37RhTPO in combination with Rituximab
(Rituxan (TN))		2件: Recombinant Human Thrombopoietin,
Rituximab (Rituxan Sc)		1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 63 💬
38Rituxan1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬4件: 46, 60, 256, 288 💬
39Rituxan (INN: Rituximab), brand name in the United States1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
40Rituxan (INN: Rituximab), brand name in the US1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
41Rituxan (rituximab)1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 49 💬
42Rituxan (US, Canada, Japan), MabThera (rest of the world)1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
43Rituxan (US, Canada, Japan), MabThera (rest of world)1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 53 💬
44Rituxan®1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
45Rituxan® (rituximab)1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
46RITUXIMAB
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬48件: 11, 13, 14, 19, 26, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 💬
47Rituximab (anti-CD20)
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 53 💬
48Rituximab (Arm A)
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬2件: 43, 44 💬
49Rituximab (Arm B)
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬2件: 43, 44 💬
50Rituximab (EU)
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
51Rituximab (genetical recombination)
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 14 💬
52Rituximab (MABTHERA® or RITUXAN®).1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬2件: 35, 61 💬
53Rituximab (Mabthera®)
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 61 💬
54Rituximab (Rituxan)1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 11 💬
55Rituximab (RTX) and Azathioprine (AZA)
(Rituxan (TN))		2件: Azathioprine,
Rituximab (Rituxan Sc)		2件: Azathioprine ,
Rituximab (Rituxan (TN)) 💬 		1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 65 💬
56Rituximab (US)
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
57Rituximab - MabThera
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
58Rituximab 1g IV
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 162 💬
59Rituximab [MabThera/Rituxan]1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬2件: 46, 63 💬
60Rituximab [MabThera]
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
61Rituximab and Cyclophosphamide IV
(Rituxan (TN))		2件: Cyclophosphamide,
Rituximab (Rituxan Sc)		3件: Cyclophosphamide ,
Rituximab (Rituxan (TN)),
Cyclophosphamide 💬 		1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 35 💬
62Rituximab and Hyaluronidase Human
(Rituxan (TN))		2件: Hyaluronidase,
Rituximab (Rituxan Sc)		4件: Rituximab (Rituxan (TN)),
Hyaluronidase ,
Hyaluronidase ,
Hyaluronidase 💬 		1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 331 💬
63Rituximab combined with Omalizumab
(Rituxan (TN))		2件: Omalizumab,
Rituximab (Rituxan Sc)		2件: Rituximab (Rituxan (TN)),
Omalizumab 💬 		2件: FCER1A,
MS4A1 💬 		5件: Asthma, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬1件: 162 💬
64Rituximab combined with tacrolimus induction + rituximab maintenance
(Rituxan (TN))		2件: Rituximab (Rituxan Sc),
Tacrolimus		3件: Tacrolimus ,
Rituximab (Rituxan (TN)),
Tacrolimus 💬 		6件: MS4A1,
PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬 		34件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬1件: 222 💬
65Rituximab combined with tacrolimus induction + tacrolimus maintenance
(Rituxan (TN))		2件: Rituximab (Rituxan Sc),
Tacrolimus		3件: Tacrolimus ,
Rituximab (Rituxan (TN)),
Tacrolimus 💬 		6件: MS4A1,
PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬 		34件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬1件: 222 💬
66Rituximab Infusion
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬2件: 13, 222 💬
67Rituximab IT
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 13 💬
68Rituximab IV
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 13 💬
69Rituximab konsentrat til infusjonsvaeske oppløsning 10 mg/ml
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 13 💬
70Rituximab MabThera
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
71Rituximab, Cyclophosphamide, and Corticosteroids
(Rituxan (TN))		2件: Cyclophosphamide,
Rituximab (Rituxan Sc)		3件: Cyclophosphamide ,
Rituximab (Rituxan (TN)),
Cyclophosphamide 💬 		1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 222 💬
72Rituximab, Mabthera
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 53 💬
73Rituximab, MTX, folic acid
(Rituxan (TN))		2件: Folic acid,
Rituximab (Rituxan Sc)		2件: Folic acid ,
Rituximab (Rituxan (TN)) 💬 		1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
74Rituximab, observational study amon patients with active RA
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
75Rituximab-EU+ Rituximab-Pfizer x 2 Courses
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
76Rituximab-Pfizer
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
77Rituximab-Pfizer (PF-05280586) x 3 courses
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
78Rituximab-US + Rituximab-Pfizer x 2 Courses
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
79Rituximab/ Mabthera
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 271 💬
80SAIT101 (proposed rituximab biosimilar)
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
81SAIT101 (rituximab biosimilar)
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
82Standard dose of rituximab
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 49 💬
83The Standard Steroid Treatment, Plasma Exchange and rituximab
(Rituxan (TN))		1件: Rituximab (Rituxan Sc)1件: Rituximab (Rituxan (TN)) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 85 💬